PPARδ agonist comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-01-08. Numbers and descriptions here follow the published literature rather than marketing material.
GW501516 binds and activates PPARδ, a nuclear receptor that influences transcription of genes involved in fatty acid oxidation and energy use. Activation shifts some metabolic pathways in preclinical models, which is why the compound has been studied for lipid disorders and exercise-related endpoints. The exact downstream effects in humans are incompletely mapped. PPARδ is expressed in many tissues, including skeletal muscle, liver, and adipose tissue, so broad activation may have varied consequences. Researchers continue to examine how selective or partial activation might alter the balance between benefits and risks.
Published human data are sparse and mostly come from early-phase trials. Those studies examined short-term changes in lipids, glucose, and exercise capacity, but they were not large enough to establish efficacy or long-term safety. Some animal experiments reported increased running endurance, yet such findings do not prove a performance benefit in people. Anti-doping laboratories detect GW501516 and its metabolites in urine or blood using liquid chromatography-tandem mass spectrometry. Detection windows depend on dose, sample type, and individual metabolism. The method is sensitive enough to identify trace residues in tested samples.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white solid | Typical form of reference material |
| Solubility | Low in water; soluble in DMSO | Used to prepare stock solutions |
| Typical storage | -20 °C, desiccated, protected from light | Common laboratory practice |
| Analytical method | LC-MS/MS | Detects parent compound and metabolites |
| Common test matrix | Urine or blood | Used in anti-doping analysis |
Anti-doping laboratories identify GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the usual matrix, and detection can occur after the parent compound has cleared from blood. The exact detection window depends on dose, formulation, individual metabolism, and assay sensitivity. Because the compound is prohibited at all times, athletes are subject to testing in and out of competition. Analytical methods continue to improve as new metabolites and designer analogs are characterized.
GW501516 acts as a ligand for PPAR delta, a nuclear receptor that regulates transcription of genes involved in fatty acid oxidation and energy use. Activation of this receptor in skeletal muscle shifts metabolism toward fat burning in animal models. The compound does not burn fat directly; it changes gene expression over hours to days. Researchers study it to understand metabolic flexibility and exercise adaptation. Effects observed in rodents are not automatically expected in humans.
Preclinical research reported that GW501516 increased running endurance in mice and improved lipid profiles in some animal species. Early human trials explored effects on high-density lipoprotein cholesterol, triglycerides, and glucose handling, but the program was discontinued. Published human data are sparse and do not establish efficacy for any condition. Studies also examined PPAR delta in cancer biology, with conflicting findings across models. The relationship between receptor activation, tissue context, and disease risk remains an active area of investigation.
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.
Handling and quality assessment of cardarine reference material follow general laboratory practices for poorly characterized compounds. It typically appears as a white to off-white powder and is sparingly soluble in water but soluble in organic solvents such as dimethyl sulfoxide and ethanol. Storage recommendations usually specify a cool, dry, dark place, with long-term storage at low temperature and desiccation. Purity may be checked by high-performance liquid chromatography with ultraviolet detection, while identity is confirmed by mass spectrometry and nuclear magnetic resonance. No pharmacopeial monograph exists, so reported purity and stability depend on the supplier’s methods.
GW501516 acts as a selective agonist at PPARδ, a nuclear receptor that regulates transcription of genes involved in lipid handling and energy metabolism. Activation of PPARδ in preclinical models increases fatty acid oxidation, mitochondrial biogenesis, and exercise endurance in rodents. These effects have made the compound a subject of metabolic research and also a target for sport anti-doping rules. In humans, however, controlled studies are limited, and whether similar endurance or metabolic changes occur at tolerated exposures remains an open question. The receptor’s broad tissue distribution also means downstream effects may vary by organ and condition.
Cardarine is frequently described as a fat-burning or endurance-enhancing supplement, but these claims exceed the available evidence. The compound is not a hormone, steroid, or selective androgen receptor modulator. Research articles discuss it as a tool compound for studying PPARδ biology, while anti-doping literature focuses on its abuse and detection. Quality of unapproved products is uncertain, and independent analyses have found impurities or incorrect labeling. Open questions include whether human cancer risk resembles that seen in rodents and how often non-athletes use the substance.
Cardarine has no approved therapeutic indication and is not marketed as a medicine. The World Anti-Doping Agency lists GW501516 as a prohibited substance at all times, covering both in-competition and out-of-competition periods. National laws vary: some countries treat it as an unapproved drug subject to import controls, while others have specific restrictions on sale for human consumption. It is often sold as a research chemical, a label that does not imply safety or legality. Enforcement actions have targeted online vendors and shipments.
Collins described her return to the show as "redemption" after withdrawing from her original series, comparing herself to Lara Croft and noted that although the series was tougher this time around, she felt she had "unfinished business" and ultimately "shut it down". She entered camp on the second day of the series alongside Craig Charles, who had also appeared on her original series. Collins completed a helicopter ride into camp, before she and Charles took part in an eating trial, which was won by the latter. She resided in the basic camp "Savannah Scrub" alongside Adam Thomas, Beverley Callard and Seann Walsh for several days, until they joined the main camp after completing a trial in which they were situated in water tanks and had to transport keys to one another. Following her arrival in main camp, Collins fell out of her hammock during one of the episodes. She completed her third trial alongside Scarlett Moffatt, during which time the camp was split into teams. She ultimately lost this trial; however her team the "Rhinos" were victorious and ultimately won a banquet and a trip on safari. Following a safety chain elimination in which Collins was saved by Jimmy Bullard and David Haye was eliminated, Haye then had to choose another campmate to leave alongside him. He chose Collins, who ultimately became the third campmate to be eliminated from the series after spending nine days in camp. Later in the year, Collins is set to begin starring in a Sky One reality series, Gemma Collins: Everything.
=== Pregnancy === Antidepressant exposure (including vilazodone) is associated with shorter average duration of pregnancy (by three days), increased risk of preterm delivery (by 55%), lower birth weight (by 75 g), and lower Apgar scores (by <0.4 points). It is uncertain whether there is an increased rate of septal heart defects among children whose mothers were prescribed an SSRI in early pregnancy.
Neuromarketing consultant Zack Lynch argues that neurotechnologies will have a more immediate effect on society than gene therapy and will face less resistance as a pathway of radical human enhancement. He also argues that the concept of "enablement" needs to be added to the debate over "therapy" versus "enhancement". The prospect of human enhancement has sparked public controversy. The main ethical question in the debate about human enhancement involves which legal restrictions, if any, should exist. Dale Carrico wrote that "human enhancement" is a loaded term which has eugenic overtones because it may imply the improvement of human hereditary traits to attain a universally accepted norm of biological fitness (at the possible expense of human biodiversity and neurodiversity), and therefore can evoke negative reactions far beyond the specific meaning of the term. Michael Selgelid terms this as a phase of "neugenics" suggesting that gene enhancements occurring now have already revived the idea of eugenics in our society. Practices of prenatal diagnosis, selective abortion and in-vitro fertilization aims to improve human life allowing for parents to decide via genetic information if they want to continue or terminate the pregnancy. A criticism of human enhancement is that it will create unfair physical or mental advantages, or unequal access to such enhancements, can and will further the gulf between the "haves" and "have-nots".
=== Pharmacological === The medications available differ between substances. For opioid use disorder, opioid agonist maintenance treatment with methadone or buprenorphine is common. It retains people in treatment and suppresses illicit opioid use more effectively than placebo. A systematic review and meta-analysis of 15 trials and 36 cohort studies found that time spent receiving opioid agonist treatment was associated with lower all-cause and overdose mortality, with the risk of death around six times higher in the four weeks after treatment stopped. A Cochrane review also found that opioid substitution therapy reduces the risk of acquiring hepatitis C among people who inject drugs, with a larger reduction when combined with high-coverage needle and syringe programmes. For alcohol use disorder, oral naltrexone and acamprosate are recommended as first-line medications alongside psychosocial support, whereas trial evidence that disulfiram reduces drinking is weaker. For tobacco (nicotine) dependence, varenicline, cytisine and nicotine e-cigarettes are among the most effective aids for quitting long-term, followed closely by using two forms of nicotine replacement therapy at once (for example a patch together with gum or a lozenge). Bupropion is also used. No medication has been approved for cocaine or amphetamine (stimulant) use disorder, for which psychosocial treatment remains the principal care.
Sources: en.wikipedia.org
The TOPS System (Total Posterior Spine System) is a spinal implant designed to stabilize the lower spine and maintain range of motion following lumbar decompression surgery for spinal stenosis and related conditions. Unlike spinal fusion, which eliminates motion at the treated level, TOPS aims to preserve mobility while providing stability. The device is manufactured by Premia Spine and has received approval for clinical use in the United States by the Food and Drug Administration (FDA) and in the European Union under the CE (Conformité Européenne) marking.
Friedrich Wöhler discovered that an organic substance, urea, could be produced from inorganic starting materials in 1828. That was an important conceptual milestone in chemistry by being the first example of a synthesis of a substance that had been known only as a byproduct of living processes. Wöhler obtained urea by treating silver cyanate with ammonium chloride, a simple, one-step synthesis:
== Biological activity == Cortisol acts as an agonist of the corticosteroid receptors, including the glucocorticoid receptor (GR) and mineralocorticoid receptor (MR). Cortisol is also an agonist of membrane corticosteroid receptors, including membrane glucocorticoid receptors (mGRs) and membrane mineralocorticoid receptors (mMRs). In addition to its corticosteroid receptor agonism, cortisol has been reported to be a highly potent biphasic regulator of the GABAA receptor, acting as a positive allosteric modulator at low concentrations (1–10 pM) and as a negative allosteric modulator at high concentrations (10–1,000 nM).
== Syndesmosis == A syndesmosis is a slightly mobile fibrous joint in which bones such as the tibia and fibula are joined together by connective tissue. An example is the distal tibiofibular joint. Injuries to the ankle syndesmosis are commonly known as a "high ankle sprain". Although the syndesmosis is a joint, in the literature the term syndesmotic injury is used to describe injury of the syndesmotic ligaments. It comes from the Greek σύν, syn (meaning "with") and δεσμός, desmos (meaning "a band"). Syndesmosis sprains have received increasing recognition during recent years because of a heightened awareness of the mechanism, symptoms, and signs of injury.
=== Oxidative stress === Oxidative stress causes the accumulation of reactive oxygen species (ROS), resulting in oxidative damage to DNA, proteins involved in cellular repair, and lipids that support the skin barrier. Oxidative stress can hinder the fibroblasts' collagen production, endothelial cell angiogenesis, and keratinocytes' re-epithelialization. The result of oxidative stress is a state of cellular senescence, where cells secrete pro-inflammatory factors and are unable to divide. Senescent cells signal to immune cells, perpetuating a non-resolving wound that can develop into an ulcer.
Sources: en.wikipedia.org
== Epidemiology == The first estimate of US prevalence for autoimmune diseases as a group was published in 1997 by Jacobson, et al. They reported US prevalence to be around 9 million, applying prevalence estimates for 24 diseases to a US population of 279 million. Jacobson's work was updated by Hayter & Cook in 2012. This study used Witebsky's postulates, as revised by Rose & Bona, to extend the list to 81 diseases and estimated overall cumulative US prevalence for the 81 autoimmune diseases at 5.0%, with 3.0% for males and 7.1% for females. In 2025, a study using electronic medical records from over 15 million patients at six large academic medical systems in the United States found a prevalence of 4.6% for autoimmune disease, based on a list of 105 conditions from The Rose and Mackay Textbook of Autoimmune Diseases. The study also found that over 34% of patients with an autoimmune disease had at least one other autoimmune condition, compared to cancer, where 8.1% of patients are diagnosed with a second primary malignancy.
Berkelium(IV) fluoride (BkF4) is a yellow-green ionic solid and is isotypic with uranium tetrafluoride or zirconium tetrafluoride. Berkelium(III) fluoride (BkF3) is also a yellow-green solid, but it has two crystalline structures. The most stable phase at low temperatures is isotypic with yttrium(III) fluoride, while upon heating to between 350 and 600 °C, it transforms to the structure found in lanthanum trifluoride. Visible amounts of berkelium(III) chloride (BkCl3) were first isolated and characterized in 1962, and weighed only 3 billionths of a gram. It can be prepared by introducing hydrogen chloride vapors into an evacuated quartz tube containing berkelium oxide at a temperature about 500 °C. This green solid has a melting point of 600 °C, and is isotypic with uranium(III) chloride. Upon heating to nearly melting point, BkCl3 converts into an orthorhombic phase. Two forms of berkelium(III) bromide are known: one with berkelium having coordination 6, and one with coordination 8. The latter is less stable and transforms to the former phase upon heating to about 350 °C. An important property of radioactive solids has been studied on these two crystal forms: the structure of fresh and aged 249BkBr3 samples was probed by X-ray diffraction over a period longer than 3 years, so that various fractions of berkelium-249 had beta decayed to californium-249. No change in structure was observed upon the 249BkBr3—249CfBr3 transformation. However, other differences were noted for 249BkBr3 and 249CfBr3.
== PPIs binding mode == The disulfide binding of the inhibitor takes place in the luminal sector of the H+/K+ ATPase where 2 mol of inhibitor is bound per 1 mol of active site H+/K+ ATPase. All PPIs react with cysteine 813 in the loop between TM5 and TM6 on the H+/K+ ATPase, fixing the enzyme in the E2 configuration. Omeprazole reacts with cysteine 813 and 892. Rabeprazole binds to cysteine 813 and both 892 and 321. Lansoprazole reacts with cysteine 813 and cysteine 321, whereas pantoprazole and tenatoprazole react with cysteine 813 and 822. Reaction with cysteine 822 confers a rather special property to the covalently inhibited enzyme, namely irreversibility to reducing agents. The likely first step is binding of the prodrug protonated on the pyridine of the compound with cysteine 813. Then the second proton is added with acid transport by the H+/K+ ATPase, and the compound is activated. Recent data suggest the hydrated sulfenic acid to be the reactive species forming directly from the mono-protonated benzimidazole bound on the surface of the pump.
Similarly, mixing starch into concentrated sulfuric acid gives elemental carbon and water. The effect of this can also be seen when concentrated sulfuric acid is spilled on paper. Paper is composed of cellulose, a polysaccharide related to starch. The cellulose reacts to give a burnt appearance in which the carbon appears much like soot that results from fire. Although less dramatic, the action of the acid on cotton, even in diluted form, also destroys the fabric.
Sources: en.wikipedia.org
Anti-doping and clinical laboratories commonly use liquid chromatography-tandem mass spectrometry. The method can identify GW501516 and its metabolites in urine or blood. Detection depends on sample timing and the amount present.
PPARδ is a nuclear receptor that regulates genes linked to fatty acid oxidation and energy metabolism. Activation can alter lipid handling and energy use in experimental models. The full range of effects in humans is still under study.
The solid compound is generally stable when kept cold, dry, and protected from light. Solutions may degrade faster, so laboratory protocols often specify fresh preparation or cold storage. Stability can depend on solvent, concentration, and container.
Cardarine is commonly known as GW501516 or GW-1516. These names refer to the same synthetic compound. It is not a brand-name approved medicine.